Latest Close
₹1,345.00
+2.67%
Connecting…
Day Range
-
Full OHLC pending
Volume
-
Full session data pending
50 DMA
₹1,184.04
200 DMA
₹1,247.25
1 year gain / loss
+₹142.80(+11.88%)
₹1,202.20 → ₹1,345.00· 2025-10-30 to 2026-10-30
Charting by TradingView
This stock does not satisfy the default swing-support rules at the selected chart endpoint. Its price, volume and moving averages remain available for manual research.
Snapshot 2026-10-31 · Financial period Jun 2026 · Consolidated figures where available
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
Market Cap
₹1,12,698.53 Cr
P/E
40.84×
Sector -37.21× · above
P/B
2.90×
Sector 4.17× · below
EV / EBITDA
18.95×
Sector 16.20× · above
ROE
7.21%
Sector 0.27%
ROCE
8.58%
Sector 6.41%
ROA
4.79%
Sector -17.13%
Cash Flow / Profit
1.36×
| Period | Revenue | Operating profit | Net profit |
|---|---|---|---|
| Jun 2026 | 8,454.5 +5.4% | 553.3 | 435.6 +96.8% |
| Mar 2026 | 8,021.8 -11.1% | 199.7 | 221.3 -81.4% |
| Dec 2025 | 9,022.2 -1.4% | 1,543.2 | 1,189.6 -11.0% |
| Sep 2025 | 9,152.2 | 1,744.8 | 1,336.8 |
Dividend
10 Jul 2026 · ₹8